1,673 reports of this reaction
6.4% of all BREXPIPRAZOLE reports
#1 most reported adverse reaction
WEIGHT INCREASED is the #1 most commonly reported adverse reaction for BREXPIPRAZOLE, manufactured by Otsuka America Pharmaceutical, Inc.. There are 1,673 FDA adverse event reports linking BREXPIPRAZOLE to WEIGHT INCREASED. This represents approximately 6.4% of all 26,345 adverse event reports for this drug.
Patients taking BREXPIPRAZOLE who experience weight increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
WEIGHT INCREASED is moderately reported among BREXPIPRAZOLE users, representing a notable but not dominant share of adverse events.
In addition to weight increased, the following adverse reactions have been reported for BREXPIPRAZOLE:
The following drugs have also been linked to weight increased in FDA adverse event reports:
WEIGHT INCREASED has been reported as an adverse event in 1,673 FDA reports for BREXPIPRAZOLE. This does not prove causation, but indicates an association observed in post-market surveillance data.
WEIGHT INCREASED accounts for approximately 6.4% of all adverse event reports for BREXPIPRAZOLE, making it one of the most commonly reported side effect.
If you experience weight increased while taking BREXPIPRAZOLE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.